Información de la revista
Visitas
154
Resident's Forum
Acceso a texto completo
Pruebas no corregidas. Disponible online el 20 de marzo de 2025
RF – Metformin as Part of the Therapeutic Armamentarium of Hidradenitis Suppurativa
FR – Metformina en el tratamiento de la hidradenitis supurativa
Visitas
154
J.M. Camino Salvador
Autor para correspondencia
jose.caminosalvador@gmail.com

Corresponding author.
, A. Martínez Fernández, C. Chiloeches Fernández
Servicio de Dermatología, Hospital Universitario de Guadalajara, Guadalajara, Spain
Contenido relacionado
J.M. Camino Salvador, A. Martínez Fernández, C. Chiloeches Fernández
Este artículo ha recibido
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Tablas (1)
Table 1. Summary of published case series of patients with HS treated with metformin.
Tablas
Texto completo

Hidradenitis suppurativa (HS) is a chronic inflammatory disease of the hair follicle characterized by nodules, abscesses, fistulas, and scars. Its main comorbidities include obesity, diabetes mellitus (DM), metabolic syndrome (MS), and polycystic ovary syndrome (PCOS).1

Metformin—the main treatment for type 2 diabetes (T2DM)—due to its ability to improve tissue sensitivity to insulin, also exhibits pleiotropic anti-inflammatory and immunoregulatory properties, according to the recent work by Petrasca et al.1 This study highlights the ability of metformin to attenuate glycolysis and the mammalian target of rapamycin (mTOR) pathway. Additionally, the ability of metformin to normalize the expression profiles of interleukin (IL)-17A, interferon-gamma, and IL-6 in neutrophils and skin explants from HS patients was demonstrated.2

The use of metformin as a second-line therapy in HS in clinical practice is a common thing.1 However, despite being included in the American (recommendation level 3) and British clinical practice guidelines (good practice point), no clinical trials have ever evaluated its efficacy profile.3,4

The current evidence comes from 6 case series (Table 1),1,5 covering a total of 228 patients treated with metformin, mostly women (83.3%), with a mean age of 38.4 years. More than 50% of the cases had overweight or obesity, and comorbidities such as PCOS (21.2%) or DM (9.6%). One series registered a total of 16 pediatric patients. The Hurley scale was the most widely used to define severity, with Hurley stage II being the most represented (139 patients).

Table 1.

Summary of published case series of patients with HS treated with metformin.

    Demographics  Comorbidities  Severity  Regimen  Dosage (mg/day)  Response rate  Improvement in DLQI  Treatment duration (months)  Survival rate  Discontinuation 
Senent-Valero et al., 20231  Retrospective case series  N=9692% women, 37 years  Overweight or obesity (91%)MS (23%) PCOS (19%)  Hurley II (93%)SS14.5±11.1  Adjunctive (94%). Resorcinol (N=77)  850  NS  NS  12 (5.3–22.8)  51% at 12 months, 21.9% at 24 months  Lack of response (34%)ADR (16%) 
Segura-Palacios et al., 20216  Retrospective case series  N=2766% women, 32.1 years  Overweight or obesity (70.4%)  Hurley I (51.8%), Hurley II (48.2%)  Monotherapy  1700–2550  40.7% reduction in HS-PGA score by 1 point  DLQI reduction: 13 to 9 (p=0.001)  NS  ADR (14.8%), Desire for pregnancy (3.7%) 
Jennings et al., 20207  Retrospective case series  N=5385% women, 37 years  Mean weight 102kgDM (7%), PCOS (9.5%)  Hurley I (4%)Hurley II (72%), Hurley III (24%)  Monotherapy, later addition: Dapsone (N=7), Antibiotics (N=2), Acitretin (N=1), Adalimumab (N=1)  1500 (500–3000)  Subjective clinical improvement: 68% (N=36)CR: 19%, PR: 58% Hurley II, 55%Hurley III  NS  11.3  61% at 6 months, 39% at 12 months  ADR (5.6%) Lack of response (20.7%) 
Moussa et al., 20208  Retrospective case series  N=1675% women, 13.7 years  Obesity (81%)DM (63%)PCOS (25%)AN (50%)  Hurley I (69%), Hurley II (31%), Hurley III (0%)  Monotherapy or adjunctive, N/S  500–1000  31% reduction in number of outbreaks  NS  N/S  NS  Lack of response (6.2%)ADR (12.5%) 
Sanz-Bueno et al., 20179  Retrospective case series  N=1145% women  N/S  N/S  Monotherapy  450–2550  SS improvement: 18% (N=2)  DLQI reduction: 5.5 points in 36%  N/S  NS  Flare-up (18%) 
Verdolini et al., 201310  Prospective case series  N=2588% women 31.5 years  Overweight (88%)GI (88%) PCOS (88%)  SS34.40 (17–58)  Monotherapy  500–1500  SS improvement: 76%(N=19) Severe to mild-moderate change in 48%(N=12)  DLQI reduction > 50% in 64%  >6 months  NS  Lack of response (28%) 

AN: acanthosis nigricans; DLQI: Dermatology Life Quality Index; DM: diabetes mellitus; HS-PGA: Hidradenitis Suppurativa Physician Global Assessment; GI: glucose intolerance; ADR: adverse drug reactions; MS: metabolic syndrome; PCOS: polycystic ovary syndrome; NS: not specified; N/S: non-significant.

There are significant disparities in the evaluation methods used, with standardized tools—Sartorius Score, Physician Global Assessment—being employed in only 3 of the studies. The others used activity descriptors (number of outbreaks, suppuration, and pain). Despite the reported heterogeneity, most studies reported clinical improvements in 31–76% of the patients. Lack of response was the most common cause for discontinuation (6.2–34%). Metformin was well tolerated, with transient digestive discomfort being the most reported adverse effect. Although the pediatric series described 2 cases of mood swings, they did not require discontinuation. Three studies described changes in the Dermatology Quality of Life Index (DLQI), and a reduction of 4 points turned out to be significant (p<0.01) in a series of 27 subjects. This same series showed a 12-month survival rate of 31%. Only 2 series have provided survival data, the most recent being the one by Senent-Valero et al., who showed drug persistence rates of 51% and 21.9% at 12 and 24 months, respectively, in a cohort of 96 patients, the largest published to this date.5

Therefore, despite the heterogeneity of the available data, metformin happens to be an affordable and well-tolerated therapeutic option with promising properties for patients with mild-to-moderate HS. The low percentage of patients with comorbidities (DM, PCOS) included in the series may underestimate the real effect of the drug in these subgroups. Although the collected data support the use of metformin in HS, further studies are needed to accurately evaluate safety and efficacy profile.

Conflict of interest

The authors declare that they have no conflict of interest.

References
[1]
A. Tsentemeidou, E. Vakirlis, I. Papadimitriou, D. Ioannides, E. Sotiriou.
Metformin in hidradenitis suppurativa: is it worth pursuing further?.
Skin Appendage Disord, 9 (2023), pp. 187-190
[2]
A. Petrasca, R. Hambly, N. Kearney, C.M. Smith, E.K. Pender, J. Mac Mahon, et al.
Metformin has anti-inflammatory effects and induces immunometabolic reprogramming via multiple mechanisms in hidradenitis suppurativa.
Br J Dermatol, 189 (2023), pp. 730-740
[3]
A. Alikhan, C. Sayed, A. Alavi, R. Alhusayen, A. Brassard, C. Burkhart, et al.
North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management.
J Am Acad Dermatol, 81 (2019), pp. 91-101
[4]
J.R. Ingram, F. Collier, D. Brown, T. Burton, J. Burton, M.F. Chin, et al.
British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018.
Br J Dermatol, 180 (2019), pp. 1009-1017
[5]
M. Senent-Valero, A. Matijasevich, N. Jara-Rico, F. Sivera, J.C. Pascual.
Drug survival of metformin in patients with hidradenitis suppurativa.
Br J Dermatol, 190 (2023), pp. 125-127
[6]
J.M. Segura Palacios, M. Colmenero Sendra, J. del Boz González, F. Rivas Ruiz, M. de Troya Martín.
Metformin for the treatment of hidradenitis suppurativa: our experience with 27 patients.
Actas Dermosifiliogr, 112 (2021), pp. 202-208
[7]
L. Jennings, R. Hambly, R. Hughes, B. Moriarty, B. Kirby.
Metformin use in hidradenitis suppurativa.
J Dermatolog Treat, 31 (2020), pp. 261-263
[8]
C. Moussa, L. Wadowski, H. Price, L. Mirea, J. O’Haver.
Metformin as adjunctive therapy for pediatric patients with hidradenitis suppurativa.
J Drugs Dermatol, 19 (2020), pp. 1231-1234
[9]
Sanz Bueno J, Gutiérrez Medina S, Sánchez-Gilo A, Vicente Martín F. Metformin failed to improve hidradenitis suppurativa in a cohort of eleven patients. In: 26th EADV Congress; 2017: Abstract BL 1125.
[10]
R. Verdolini, N. Clayton, A. Smith, N. Alwash, B. Mannello.
Metformin for the treatment of hidradenitis suppurativa: a little help along the way.
J Eur Acad Dermatol Venereol, 27 (2013), pp. 1101-1108
Copyright © 2025. AEDV
Descargar PDF
Idiomas
Actas Dermo-Sifiliográficas
Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?